Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 1.
doi: 10.1097/HEP.0000000000001428. Online ahead of print.

Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in HCC

Chien-Hao Huang  1   2   3 , Wei-Ting Ku  1   4 , Jayashri Mahalingam  1   5 , Cheng-Heng Wu  1 , Tsung-Han Wu  2   6 , Jian-He Fang  1 , Chung-Wei Su  1   2 , Po-Ting Lin  1   2 , Chien-Wei Peng  1   2 , Chan-Keng Yang  2   7 , Wei Teng  1   2 , Wen-Juei Jeng  1   2 , Wei-Ting Chen  1   2 , Chen-Chun Lin  2   8 , Shi-Ming Lin  1   2 , I-Shyan Sheen  1   2 , Yung-Chang Lin  2   7 , Chun-Yen Lin  1   2
Affiliations

Tumor-migrating peripheral Foxp3-high regulatory T cells drive poor prognosis in HCC

Chien-Hao Huang et al. Hepatology. .

Abstract

Background and aims: CD4 + regulatory T cells (Tregs) are pivotal in HCC progression. However, systemic depletion of all Tregs risks autoimmunity. Existing subgroup classifications highlight Tregs' phenotypic and functional heterogeneity but lack coherent consensus. This study aimed to classify Treg subtypes using single-cell CITE-seq, integrating data from tumor, non-tumor, and blood samples in HCC patients. We also validated the clinical relevance and prognostic value of this classification.

Approach and results: CITE-seq analysis was performed on 51,067 CD4 + T cells from 8 HCC patients. Validation involved 96 HCC patients and 53 healthy donors using flow cytometry, functional assays, and clinical data. Trajectory and TCR analyses identified a peripheral Foxp3 high Treg subset that preferentially migrates to tumor sites, acquiring a terminally differentiated, activated phenotype. These tumor-infiltrating Foxp3 high Tregs exhibit elevated LAYN and TRM signatures and further increase their Foxp3 expression and immunosuppressive functions in response to pro-inflammatory cytokines in tumor tissue. The CCL5/CCR5 axis is crucial for recruiting Foxp3 high Tregs from peripheral blood into the tumor microenvironment. A strong correlation was observed between the percentage of Foxp3 high Tregs in peripheral blood and their counterparts in tumor regions, suggesting their potential as peripheral biomarkers. Notably, a peripheral Foxp3 high Tregs/CD4 + T cells percentage >3.5% predicted overall survival and early recurrence, with AUROCs exceeding 0.75.

Conclusions: Peripheral Foxp3 high Tregs migrate to tumor sites via the CCR5-CCL5 axis and mature in response to pro-inflammatory cytokines. The proportion of these Tregs in peripheral blood correlates with their presence in tumors, making them a potential biomarker for predicting HCC outcomes.

Keywords: HCC; immunotherapy; overall survival and early recurrence; peripheral Foxp3high Treg cells; single-cell cellular indexing of transcriptomes and epitopes by sequencing (CITEseq).

PubMed Disclaimer

References

    1. Rumgay H, Arnold M, Ferlay J, Lesi O, Cabasag CJ, Vignat J, et al. Global burden of primary liver cancer in 2020 and predictions to 2040. J Hepatol. 2022;77:1598–1606.
    1. Lee MS, Ryoo BY, Hsu CH, Numata K, Stein S, Verret W, et al. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): An open-label, multicentre, phase 1b study. Lancet Oncol. 2020;21:808–820.
    1. Finn RS, Qin S, Ikeda M, Galle PR, Ducreux M, Kim TY, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894–1905.
    1. Gordan JD, Kennedy EB, Abou-Alfa GK, Beg MS, Brower ST, Gade TP, et al. Systemic therapy for advanced hepatocellular carcinoma: ASCO guideline. J Clin Oncol. 2020;38:4317–4345.
    1. Alvisi G, Termanini A, Soldani C, Portale F, Carriero R, Pilipow K, et al. Multimodal single-cell profiling of intrahepatic cholangiocarcinoma defines hyperactivated Tregs as a potential therapeutic target. J Hepatol. 2022;77:1359–1372.

LinkOut - more resources